TCRX

TCRX

USD

TScan Therapeutics Inc. Common Stock

$1.120-0.050 (-4.274%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$1.170

Máximo

$1.250

Mínimo

$1.080

Volume

0.81M

Fundamentos da empresa

Capitalização de mercado

63.6M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.51M

Bolsa de valores

NGM

Moeda

USD

Faixa de 52 semanas

Mínimo $1.02Atual $1.120Máximo $6.225

Notícias relacionadas

Analyst Upgrades

BTIG Downgrades TScan Therapeutics to Neutral

BTIG analyst Justin Zelin downgrades TScan Therapeutics from Buy to Neutral.

Ver mais
BTIG Downgrades TScan Therapeutics to Neutral
Analyst Upgrades

Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6

Needham analyst Gil Blum maintains TScan Therapeutics with a Buy and lowers the price target from $9 to $6.

Ver mais
Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6
GlobeNewswire

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development;

Ver mais
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027